What’s Ahead for UroGen Pharma Ltd. (URGN) After Forming Bullish Double Top Pattern?

June 15, 2018 - By Henry Gaston

The chart of UroGen Pharma Ltd. (URGN) shows a double top with $59.88 target or 8.00 % above today’s $55.44 share price. The 5 months chart pattern indicates low risk for the $857.88 million company. It was reported on Jun, 15 by Finviz.com. If the $59.88 price target is reached, the company will be worth $68.63 million more. Double tops are rare but powerful chart patterns.

The stock decreased 0.18% or $0.1 during the last trading session, reaching $55.44. About 21,525 shares traded. UroGen Pharma Ltd. (NASDAQ:URGN) has risen 228.14% since June 15, 2017 and is uptrending. It has outperformed by 215.57% the S&P500.

Analysts await UroGen Pharma Ltd. (NASDAQ:URGN) to report earnings on August, 13. They expect $-0.91 EPS, down 30.00 % or $0.21 from last year’s $-0.7 per share. After $-0.88 actual EPS reported by UroGen Pharma Ltd. for the previous quarter, Wall Street now forecasts 3.41 % negative EPS growth.

More notable recent UroGen Pharma Ltd. (NASDAQ:URGN) news were published by: Streetinsider.com which released: “UroGen Pharma (URGN) Names Stephen Mullennix Interim CFO, Replacing Gary Titus” on June 05, 2018, also Seekingalpha.com with their article: “Urogen’s MitoGel shows treatment effect in late-stage urothelial cancer study” published on May 21, 2018, Nasdaq.com published: “UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award” on June 13, 2018. More interesting news about UroGen Pharma Ltd. (NASDAQ:URGN) were released by: Globenewswire.com and their article: “Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and …” published on June 06, 2018 as well as Nasdaq.com‘s news article titled: “UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference” with publication date: May 29, 2018.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company has market cap of $857.88 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy. It currently has negative earnings. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

UroGen Pharma Ltd. (NASDAQ:URGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.